UBS Asset Management (UBS-AM) Real Estate and Private Markets (REPM) has plans to provide £66 million (€103 million/$119 million) in forward funding for a state-of-the-art pharmaceutical facility pre-let to Autolus Therapeutics on a 20-year lease, working with development partner Reef Estates.
Autolus, a NASDAQ-listed biopharmaceutical company, is focused on developing CAR T-cell therapies for cancer treatment. This development will be the United Kingdom’s first facility built to manufacture such CAR T-cells, enabling commercialization of Autolus’ innovative technology. The facility is expected to create more than 400 jobs.
The development will focus on strong environmental credentials and targets an excellent BREEAM rating, a sustainability assessment only given to the top 10 percent of buildings. Carbon emissions will be minimal, due in part to 75 percent off-site construction, while operational carbon emissions will be significantly reduced, thanks to des
